FDA Approves T-DXd for 2 New Indications in Early-Stage HER2-Positive Breast CancerByJason M. BroderickMay 16th 2026
VIKTORIA-2 Trial Evolves to Evaluate Gedatolisib in Endocrine-Sensitive and -Resistant Breast CancerBySabrina SeraniMay 15th 2026
FDA Approves Vepdegestrant for ESR1-Mutated ER+/HER2− Advanced Breast CancerBySabrina SeraniMay 1st 2026